U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H11NO3
Molecular Weight 193.1996
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ACTARIT

SMILES

CC(=Nc1ccc(cc1)CC(=O)O)O

InChI

InChIKey=MROJXXOCABQVEF-UHFFFAOYSA-N
InChI=1S/C10H11NO3/c1-7(12)11-9-4-2-8(3-5-9)6-10(13)14/h2-5H,6H2,1H3,(H,11,12)(H,13,14)

HIDE SMILES / InChI

Molecular Formula C10H11NO3
Molecular Weight 193.1996
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: http://www.clinexprheumatol.org/article.asp?a=1640

Actarit (MS-932) is an anti-inflammatory drug developed in Japan for use in rheumatoid arthritis (RA). Actarit suppresses adjuvant arthritis through modulation of the immune system. Actarit acts on RA synovial cells to reduce cell-cell interactions with autologous synovium infiltrating lymphocytes and to inhibit proinflammatory cytokine and MMP production, leading to amelioration of symptoms of RA.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
PubMed

PubMed

TitleDatePubMed
[Effect of actarit combination therapy in patients with active rheumatoid arthritis resistant to gold agents].
2001 Jun
Glucosides of Chaenomeles speciosa remit rat adjuvant arthritis by inhibiting synoviocyte activities.
2003 Nov
[A case of rheumatoid arthritis/Sjogren's syndrome with acute renal failure due to hyperuricemia associated with mizoribine therapy].
2004 Jun
[Examination of the escape phenomenon in disease modifying antirheumatic drugs].
2005 Mar
The effect of methotrexate on bone metabolism markers in patients with rheumatoid arthritis.
2006
Photosensitizing properties of Actarit, an antirheumatic drug.
2008
Inhibitory effect of some acetyl esters and acetamides on glycation of the histone H1.
2008 Jul-Aug
Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis.
2008 Mar 20
A new low-field extremity magnetic resonance imaging and proposed compact MRI score: evaluation of anti-tumor necrosis factor biologics on rheumatoid arthritis.
2009
Modeling the solubility of pharmaceuticals in pure solvents and solvent mixtures for drug process design.
2009 Nov
Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework.
2010 Jun 15
Determination of actarit from human plasma for bioequivalence studies.
2010 Nov
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Actarit was administered at 300 mg/day and was used throughout the study period. The duration of treatment was 24 weeks. During this study there were no significant adverse reactions requiring the withdrawal of treatment.
300 mg/day, duration of treatment is 24 weeks.
Route of Administration: Oral
In Vitro Use Guide
rheumatoid arthritis primary synovial cells were co-cultured with actarit at 10(-4)-10(-7) M
Substance Class Chemical
Created
by admin
on Sat Jun 26 07:55:25 UTC 2021
Edited
by admin
on Sat Jun 26 07:55:25 UTC 2021
Record UNII
HW5B6351RZ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ACTARIT
INN   JAN   MART.   MI   WHO-DD  
INN  
Official Name English
YM-340790
Code English
ACTARIT [JAN]
Common Name English
ACTARIT [INN]
Common Name English
ACTARIT [MART.]
Common Name English
ACTARIT [MI]
Common Name English
NSC-170317
Code English
4-ACETYLAMINOPHENYLACETIC ACID
Systematic Name English
ORCL
Brand Name English
(P-ACETAMIDOPHENYL)ACETIC ACID
Common Name English
MIRABEGRON (M9)
Common Name English
ACTARIT [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29634
Created by admin on Sat Jun 26 07:55:26 UTC 2021 , Edited by admin on Sat Jun 26 07:55:26 UTC 2021
Code System Code Type Description
PUBCHEM
2018
Created by admin on Sat Jun 26 07:55:26 UTC 2021 , Edited by admin on Sat Jun 26 07:55:26 UTC 2021
PRIMARY
EPA CompTox
18699-02-0
Created by admin on Sat Jun 26 07:55:26 UTC 2021 , Edited by admin on Sat Jun 26 07:55:26 UTC 2021
PRIMARY
ECHA (EC/EINECS)
242-511-3
Created by admin on Sat Jun 26 07:55:26 UTC 2021 , Edited by admin on Sat Jun 26 07:55:26 UTC 2021
PRIMARY
FDA UNII
HW5B6351RZ
Created by admin on Sat Jun 26 07:55:26 UTC 2021 , Edited by admin on Sat Jun 26 07:55:26 UTC 2021
PRIMARY
ChEMBL
CHEMBL1885632
Created by admin on Sat Jun 26 07:55:26 UTC 2021 , Edited by admin on Sat Jun 26 07:55:26 UTC 2021
PRIMARY
MERCK INDEX
M1394
Created by admin on Sat Jun 26 07:55:26 UTC 2021 , Edited by admin on Sat Jun 26 07:55:26 UTC 2021
PRIMARY Merck Index
WIKIPEDIA
ACTARIT
Created by admin on Sat Jun 26 07:55:26 UTC 2021 , Edited by admin on Sat Jun 26 07:55:26 UTC 2021
PRIMARY
EVMPD
SUB05255MIG
Created by admin on Sat Jun 26 07:55:26 UTC 2021 , Edited by admin on Sat Jun 26 07:55:26 UTC 2021
PRIMARY
CAS
18699-02-0
Created by admin on Sat Jun 26 07:55:26 UTC 2021 , Edited by admin on Sat Jun 26 07:55:26 UTC 2021
PRIMARY
INN
6549
Created by admin on Sat Jun 26 07:55:26 UTC 2021 , Edited by admin on Sat Jun 26 07:55:26 UTC 2021
PRIMARY
DRUG CENTRAL
84
Created by admin on Sat Jun 26 07:55:26 UTC 2021 , Edited by admin on Sat Jun 26 07:55:26 UTC 2021
PRIMARY
NCI_THESAURUS
C73298
Created by admin on Sat Jun 26 07:55:26 UTC 2021 , Edited by admin on Sat Jun 26 07:55:26 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> METABOLITE
URINE
Related Record Type Details
ACTIVE MOIETY